Publikationsdatenbank

Treatment of 5 dogs with immune-mediated thrombocytopenia using Romiplostim (2016)

Art

Zeitschriftenartikel / wissenschaftlicher Beitrag

Autoren

Kohn, Barbara (WE 20)

Bal, Gürkan

Chirek, Aleksandra (WE 20)

Rehbein, Sina (WE 20)

Salama, Abdulgabar

Quelle

BMC veterinary research; 12(1) — S. 96

ISSN: 1746-6148

Sprache

Englisch

Verweise

DOI: 10.1186/s12917-016-0718-4

Pubmed: 27283401

Kontakt

Klinik für kleine Haustiere

Oertzenweg 19 b
Haus 1
14163 Berlin
+49 30 838 62356
kleintierklinik@vetmed.fu-berlin.de

Abstract / Zusammenfassung

Immune thrombocytopenia (ITP) in dogs is analogous to that in humans. Romiplostim, a novel thrombopoietin receptor (TPO-R) agonist, is currently used for the treatment of refractory ITP in humans, but not in dogs. Here, we describe the response to romiplostim in five dogs with refractory ITP. Five dogs with severe and refractory ITP (three primary and two secondary) received romiplostim subcutaneously. Four dogs were administered 3-5 μg/kg and one dog received 10-13 μg/kg body weight once weekly.

Romiplostim was well-tolerated and administration was associated with an increase in platelet counts in all five dogs. Four of the five dogs entered remission and relapses were not observed over a follow-up period of 3-10 months.

Romiplostim is effective in the treatment of ITP in dogs at least as well as in humans. This finding may help to develop and use new therapeutics for ITP in dogs and humans.